MP46-03 PIVOTAL TRIAL OF MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION IN MEN WITH LOCALIZED PROSTATE CANCER: THREE-YEAR FOLLOW-UP

You have accessJournal of UrologyProstate Cancer: Localized: Ablative Therapy (MP46)1 Sep 2021MP46-03 PIVOTAL TRIAL OF MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION IN MEN WITH LOCALIZED PROSTATE CANCER: THREE-YEAR FOLLOW-UP Laurence Klotz, Christian P. Pavlovich, Joseph Chin, Gencay Hatiboglu, Michael Koch, David Penson, Steven S. Raman, Aytekin Oto, Jurgen Fütterer, Marc Serrallach, James Relle, Yair Lotan, Axel Heidenreich, Bonekamp, Masoom A. Haider, JP Michiel Sedelaar, Temel Tirkes, Sandeep Arora, Katarzyna J. Macura, Daniel N. Costa, Allan Pantuck, Joyce Bomers, Gina Clarke, Robert Staruch, and Scott Eggener KlotzLaurence Klotz More articles by this author , PavlovichChristian Pavlovich ChinJoseph Chin HatibogluGencay Hatiboglu KochMichael Koch PensonDavid Penson RamanSteven Raman OtoAytekin Oto FüttererJurgen Fütterer SerrallachMarc Serrallach RelleJames Relle LotanYair Lotan HeidenreichAxel Heidenreich BonekampDavid Bonekamp HaiderMasoom Haider SedelaarJP Sedelaar TirkesTemel Tirkes AroraSandeep Arora MacuraKatarzyna Macura CostaDaniel Costa PantuckAllan Pantuck BomersJoyce Bomers ClarkeGina Clarke StaruchRobert Staruch EggenerScott View All Author Informationhttps://doi.org/10.1097/JU.0000000000002067.03AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: MRI-guided transurethral ultrasound ablation (TULSA) is a minimally-invasive procedure for prostate ablation. We report three-year outcomes from the pivotal TULSA-PRO Ablation Clinical Trial (TACT). METHODS: The study enrolled 115 men with organ-confined cancer (≤T2b, PSA ≤15 ng/ml, Grade Group 1-2) across 13 centers. Treatment was whole-gland sparing urethra urinary sphincter. Primary endpoints were safety reduction at one year. Secondary included one-year volume reduction, mpMRI, 10-core biopsy. adverse events, quality life (IPSS, IIEF, EPIC), who are salvage-free completed follow-up. RESULTS: Median (IQR) baseline age 65 (59-69) years, median 6.3 (4.6-7.9) ≥2 disease in 72/115 (63%, 69 GG2, 3 GG3). Targeted volumes 40 (32-50) cc ablated 51 (39-66) min, 98% thermal coverage ±1.4 mm spatial precision on MRI thermometry. events 9 (8%) GU infection, stricture, retention, urethral calculus pain, urinoma, all resolved before There no rectal injuries or ≥4 events. By three 15 (13%) underwent salvage treatment. At year biopsy, decreased 37 cc, GG2 eliminated 54/68 (79%) men, 72/111 (65%) had evidence any cancer. 95% nadir 0.26 ng/mL, stable 0.53 ng/mL 0.70 ng/ml (n=56) years. IPSS 7 4 (n=61) Moderate incontinence (Grade 2, pads) (2.6%) persisted years patient (<1%); there new past rate moderate erectile dysfunction responding medication) 23% 24% change IIEF-5 -2 year, zero (n=61). In follow-up potent baseline, erections sufficient penetration (IIEF Q2 ≥2) maintained 36/50 (72%) 40/50 (80%) CONCLUSIONS: With follow-up, TACT localized showed effective control low toxicity life. Source Funding: Profound Medical © 2021 American Urological Association Education Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e814-e814 Advertisement Copyright & Permissions© Inc.MetricsAuthor Information Expand Loading ...